Another FTSE 100 share whose hidden value I think will be outed

G A Chester discusses why a 37% uplift in the valuation of this FTSE 100 (INDEXFTSE:UKX) stock could be about to be unlocked.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

In an article earlier today, I explained why I think industrial technologies conglomerate Smiths Group could be undervalued by 50%+. And also why I think the value could soon be outed. It’s all to do with a demerger of one of its divisions, which I believe will prove value-enhancing for shareholders.

Smiths isn’t the only such stock on my radar at the moment. Here, I’ll explain why I believe a similar story could unfold at FTSE 100 consumer goods giant Reckitt Benckiser (LSE: RB), where I see a potential valuation uplift of 37%.

The power of brands

Companies with strong brands are highly prized by investors. This is particularly true for those selling fast-moving consumer goods. Brand loyalty and regular repeat purchases make for predictable and growing revenues, while premium prices make for high profit margins and returns on capital.

Reckitt Benckiser has been one of the best in the business for many years. It’s traded at times on a mid-20s earnings multiple, which I consider reasonable for a really top-notch operator in the sector. However, it’s fallen somewhat out of favour with investors of late.

At a current share price in the region of 6,500p, compared with nearer 8,000p at its peak two years ago, we’re looking at a rating of 18.3 times forecast 12-month earnings. If it were to re-rate to a mid-20s multiple, the share price would rise to 8,900p (37% upside from the current level).

I don’t think there’s been a change to the fundamental story that companies with high-quality stables of powerful consumer brands merit a high valuation. And I see a catalyst for Reckitt re-rating.

RB 2.0

Following the sale of its food business and acquisition of Mead Johnson Nutrition (MJN) in 2017, Reckitt embarked on what it called RB 2.0— the creation of two structurally independent business units: RB Health (incorporating MJN) and RB Hygiene Home. Implementation of this began at the start of 2018 and is expected to be complete by mid-2020.

RB Health’s brands include Nurofen, Gaviscon and Durex, as well as MJN’s infant formulas, while RB Hygiene Home has the likes of Air Wick, Cillit Bang and Finish. Now, I think these two business units housed under the same roof can do a perfectly decent job for investors. And new chief executive Laxman Narasimhan, who will take up the reins on 1 September, knows all about managing two different product categories. He comes from PepsiCo, which has a big snacks business in addition to its classic sodas and beverages.

However, I see a strong argument for progressing RB 2.0 to a full separation of RB Health and RB Hygiene into two independent companies. When such separations occur, we tend to see a heightening of management focus, entrepreneurial drive and growth in the two unleashed businesses, with a higher valuation being the happy consequence for shareholders.

Reckitt’s chairman Chris Sinclair has said, the company, “will continue to evaluate opportunities to maximise shareholder value from RB2.0” — which suggests to me the option of a full split is certainly very much on the table. I’d be happy to buy Reckitt’s shares today at 18.3 times earnings, for the company as it is. But I think a demerger or other break up of the business is on the cards, producing a valuation uplift that will reward investors at today’s share price with strong returns.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Abstract bull climbing indicators on stock chart
Investing Articles

Could the Chancellor’s Leeds Reforms trigger a bull market for UK stocks?

More competitive lending and greater interest in shares could help kick start growth for UK businesses. But could it also…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I think this AI stock could double before Palantir

Palantir stock is up almost 100% this year. As a result, it now sports a market cap of $350bn meaning…

Read more »

Elevated view over city of London skyline
Investing Articles

As the FTSE 100 hits an all-time high, is it time to reconsider the S&P 500?

Christopher Ruane explains why a surging FTSE 100 has not yet made him focus more on the potential of S&P…

Read more »

GSK scientist holding lab syringe
Investing Articles

The FTSE 100 sits at a record high. But some stocks still look dirt cheap!

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains…

Read more »

Close-up of British bank notes
Investing Articles

With a £20k Stocks and Shares ISA, here are 3 ways an investor could target a £2k annual passive income

Our writer thinks there is more than one way to try and skin a cat when it comes to earning…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Up 350% in 3 years but my favourite FTSE growth share is still on a low P/E of just 10!

Harvey Jones can't tear his eyes away from this former penny stock turned growth share superpower. But can it carry…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 83% in months, could Micron stock be the next Nvidia?

Chipmaker Micron Technology's stock price has surged by over 80% in just a few months. Could this be a possible…

Read more »

Tesla car at super charger station
US Stock

£1k invested in Tesla stock at the start of the year is currently worth…

Jon Smith reveals the performance of Tesla stock in 2025 and explains why he doesn't believe the move lower is…

Read more »